Rallybio Business Summary

Rallybio Corp (RLYB) is a clinical-stage biotechnology company that generates revenue primarily through strategic collaborations, licensing agreements, and milestone-based asset divestitures, such as its 2025 agreement with Recursion Pharmaceuticals for the REV102 program. The company operates through a single business segment focused on the discovery and development of life-transforming therapies for severe and rare disorders, with a primary concentration on complement dysregulation and hematologic conditions. Its lead clinical candidate, RLYB116, is a subcutaneously administered C5 inhibitor targeting immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Rallybio competes directly with rare disease specialists and large-cap biotechs including Alnylam Pharmaceuticals, BridgeBio Pharma, and Spark Therapeutics, positioning itself as a high-conviction developer of niche biologics that leverage validated biological pathways to address significant unmet medical needs. The company was founded in 2018 by a veteran leadership team from Alexion Pharmaceuticals, including Martin Mackay, Ph.D., Stephen Uden, M.D., and Jeffrey Fryer. The current executive team is led by CEO and Co-founder Stephen Uden, M.D., who previously served as Head of Research at Alexion and held senior R&D roles at Pfizer and Novartis. He is supported by Chief Financial Officer Jonathan I. Lieber, an experienced life sciences executive from Histogenics and Repligen, and Chief Medical Officer Steven Ryder, M.D., formerly of Alexion and Pfizer. Martin Mackay remains active as Chairman of the Board, bringing over 30 years of pedigree from AstraZeneca and Pfizer. Rallybio is backed by a notable roster of institutional investors, including 5AM Ventures, Canaan Partners, New Leaf Venture Partners, and Johnson & Johnson Innovation (JJDC), with a board of directors featuring industry leaders such as Paula Soteropoulos and Wendy K. Chung.